Skip to main content Accessibility help
×
Home

Maternal depression, antidepressant use in pregnancy and Apgar scores in infants

  • Hans M⊘rch Jensen (a1), Randi Gr⊘n (a2), Øjvind Lidegaard (a3), Lars Henning Pedersen (a4), Per Kragh Andersen (a2) and Lars Vedel Kessing (a5)...

Abstract

Background

Use of antidepressants during pregnancy has been associated with a low Apgar score in infants but a contribution from the underlying depressive disorder might influence this association.

Aims

To estimate the effects of maternal depression and use of antidepressants during pregnancy on low Apgar scores (<7) 5min after birth.

Method

Register study on all pregnant women in Denmark from 1996 to 2006 linking nationwide individualised data from the Medical Birth Register, the Psychiatric Central Register and the National Prescription database.

Results

Infants exposed to antidepressants during pregnancy had an increased rate of a low Apgar score (odds ratio (OR) = 1.72, 95% CI 1.34-2.20). The increased rate was only found among infants exposed to selective serotonin reuptake inhibitors (SSRIS) (OR =1.96, 95% CI 1.52-2.54), not among those exposed to newer (OR = 0.83, 95% CI 0.40-1.74) or older antidepressants (OR=0.53, 95% CI 0.19-1.45). Maternal depression before or during pregnancy, without prescription of antidepressants, was not associated with a low Apgar score (OR=0.44, 95% CI 0.11-1.74). Women who had only used antidepressants prior to pregnancy had no increased rate of a low Apgar score in their subsequent pregnancy, regardless of depression status.

Conclusions

Use of SSRls during pregnancy increases the risk of a low Apgar score independently of maternal depression.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Maternal depression, antidepressant use in pregnancy and Apgar scores in infants
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Maternal depression, antidepressant use in pregnancy and Apgar scores in infants
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Maternal depression, antidepressant use in pregnancy and Apgar scores in infants
      Available formats
      ×

Copyright

Corresponding author

Lars Vedel Kessing, Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK2100 Copenhagen 0, Denmark. Email: lars.vedel.kessing@regionh.dk

Footnotes

Hide All

Declaration of interest

H.M.J has been a consultant for Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Astra-Zeneca, Lundbeck, Servier, Merck Sharp & Dohme and Schering-Plough. ⊘.L. has received honoraria for speeches including fees from Bayer Pharma Denmark, MSD Denmark and Theramex, Monaco, and has been expert witness for a plaintiff in a legal US case in 2011. L.V.K. has been a consultant for Bristol-Myers Squibb, Eli Lilly, Lundbeck, Astra-Zeneca, Pfizer, wyeth, Servier and Janssen-Cilag.

Footnotes

References

Hide All
1 Cooper, WO, Willy, ME, Pont, SJ, Ray, WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196: 544–5.
2 Andrade, SE, Raebel, MA, Brown, J, Lane, K, Livingston, J, Boudreau, D, et al Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198: 194–5.
3 Alwan, S, Reefhuis, J, Rasmussen, SA, Friedman, JM. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011; 51: 264–70.
4 Kinney, HC, Belliveau, RA, Trachtenberg, FL, Rava, LA, Paterson, DS. The development of the medullary serotonergic system in early human life. Auton Neurosci 2007; 132: 81102.
5 Wadhwa, PD, Glynn, L, Hobel, CJ, Garite, TJ, Porto, M, Chicz-DeMet, A, et al Behavioral perinatology: biobehavioral processes in human fetal development. Regul Pept 2002; 108: 149–57.
6 O'Keane, V, Marsh, MS. Depression during pregnancy. BMJ 2007; 334: 1003–5.
7 Moses-Kolko, EL, Bogen, D, Perel, J, Bregar, A, Uhl, K, Levin, B, et al Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372–83.
8 Lorenzo, L, Byers, B, Einarson, A. Antidepressant use in pregnancy. Expert Opin Drug Saf 2011; 10: 883–9.
9 Koren, G, Nordeng, H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 2012; 207: 157–63.
10 Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898906.
11 Odd, DE, Rasmussen, F, Gunnell, D, Lewis, G, Whitelaw, A. A cohort study of low Apgar scores and cognitive outcomes. Arch Dis Child Fetal Neonatal Ed 2008; 93: F11520.
12 Stuart, A, Otterblad, OP, Kallen, K. Apgar scores at 5 minutes after birth in relation to school performance at 16 years of age. Obstet Gynecol 2011; 118: 201–8.
13 Odd, DE, Gunnell, D, Lewis, G, Rasmussen, F. Long-term impact of poor birth condition on social and economic outcomes in early adulthood. Pediatrics 2011; 127: e1498504.
14 Ehrenstein, V, Pedersen, L, Grijota, M, Nielsen, GL, Rothman, KJ, Sorensen, HT. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth 2009; 9: 14.
15 Ehrenstein, V. Association of Apgar scores with death and neurologic disability. Clin Epidemiol 2009; 1: 4553.
16 Knudsen, LB, Olsen, J. The Danish Medical Birth Registry. Dan Med Bull 1998; 45: 320–3.
17 Danish National Board of Health (Lægemiddelstyrelsen). Medicinal Product Statistics. Danish Health and Medicines Authority, 2011 (www.laegemiddelstyrelsen.dk).
18 Munk-Jørgensen, P, Kastrup, M, Mortensen, PB. The Danish Psychiatric Register as a tool in epidemiology. Acta Psychiatr Scand 1993; 87: 2732.
19 World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-8). WHO, 1967.
20 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
21 Statistics Denmark. Employment. Statistics Denmark, 2011 (www.dst.dk).
22 Kallen, B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312–6.
23 Lund, N, Pedersen, LH, Henriksen, TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163: 949–54.
24 Oberlander, TF, Bonaguro, RJ, Misri, S, Papsdorf, M, Ross, CJ, Simpson, EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008; 13: 6573.
25 Simon, GE, Cunningham, ML, Davis, RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–61.
26 Wisner, KL, Sit, DK, Hanusa, BH, Moses-Kolko, EL, Bogen, DL, Hunker, DF, et al Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166: 557–66.
27 Lewis, AJ, Galbally, M, Opie, G, Buist, A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust NZ J Psychiatry 2010; 44: 482–7.
28 Udechuku, A, Nguyen, T, Hill, R, Szego, K. Antidepressants in pregnancy: a systematic review. Aust NZ J Psychiatry 2010; 44: 978–96.
29 Casper, RC, Gilles, AA, Fleisher, BE, Baran, J, Enns, G, Lazzeroni, LC. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl) 2011; 217: 211–9.
30 Lu, J, Sherman, D, Devor, M, Saper, CB. A putative flip-flop switch for control of REM sleep. Nature 2006; 441: 589–94.
31 Bairy, KL, Madhyastha, S, Ashok, KP, Bairy, I, Malini, S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007; 79: 111.
32 Branchereau, P, Chapron, J, Meyrand, P. Descending 5-hydroxytryptamine raphe inputs repress the expression of serotonergic neurons and slow the maturation of inhibitory systems in mouse embryonic spinal cord. J Neurosci 2002; 22: 2598–606.
33 Maciag, D, Simpson, KL, Coppinger, D, Lu, Y, Wang, Y, Lin, RC, et al Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006; 31: 4757.
34 Noorlander, CW, Ververs, FF, Nikkels, PG, van Echteld, CJ, Visser, GH, Smidt, MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3: e2782.
35 Kallen, B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312–6.
36 Simon, GE, Cunningham, ML, Davis, RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–61.
37 Ericson, A, Kallen, B, Wiholm, BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503–8.
38 Wen, SW, Yang, QY, Garner, P, Fraser, W, Olatunbosun, O, Nimrod, C, et al Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961–6.
39 Kallen, B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312–6.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Maternal depression, antidepressant use in pregnancy and Apgar scores in infants

  • Hans M⊘rch Jensen (a1), Randi Gr⊘n (a2), Øjvind Lidegaard (a3), Lars Henning Pedersen (a4), Per Kragh Andersen (a2) and Lars Vedel Kessing (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *